In short
This article discusses a clinical trial investigating the use of BNT113, a novel drug, in combination with pembrolizumab for patients with advanced head and neck squamous cell carcinoma (HNSCC) that is positive for human papillomavirus 16 (HPV16+) and expresses PD-L1. The study aims to compare this combination therapy with pembrolizumab alone in terms of safety, tolerability, and effectiveness in treating this specific type of cancer.
At a glance
- Trial Type
- Phase II, open-label, randomized
- Study Drug
- BNT113 in combination with pembrolizumab
- Comparator
- Pembrolizumab monotherapy
- Target Population
- Patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing PD-L1
- Primary Objectives
- Assess safety, tolerability, and overall survival
- Secondary Objectives
- Evaluate anti-tumor activity, progression-free survival, and objective response rate
- Key Inclusion Criteria
- Age ≥18 years, confirmed HPV16+ HNSCC, PD-L1 expression, no prior systemic therapy for recurrent/metastatic disease
- Key Exclusion Criteria
- Pregnancy, active infections, certain autoimmune diseases, prior immunotherapy
- Primary Endpoints
- Treatment-emergent adverse events, overall survival, objective response rate
What is BNT113?
BNT113 is an investigational drug being developed for the treatment of a specific type of head and neck cancer. It is a concentrate for dispersion for injection, which means it's a liquid medication that needs to be diluted before being administered intravenously (through a vein). The drug contains two active substances, known as RBL015.2 and RBL016.2, which are classified as nucleic acids - molecules that carry genetic information.
Target Condition: HPV16-Positive Head and Neck Cancer
BNT113 is being studied for the treatment of head and neck squamous cell carcinoma (HNSCC) that is positive for human papillomavirus 16 (HPV16) and expresses a protein called PD-L1. This specific type of cancer can affect various parts of the head and neck, including the:
- Oropharynx (part of the throat behind the mouth)
- Oral cavity (mouth)
- Hypopharynx (lower part of the throat)
- Larynx (voice box)
The cancer being targeted in this study is considered unresectable (cannot be completely removed by surgery), recurrent (has come back after treatment), or metastatic (has spread to other parts of the body).
How BNT113 Works
While the exact mechanism of action is not fully described in the provided information, BNT113 is being studied in combination with another drug called pembrolizumab. Pembrolizumab is an immunotherapy drug that helps the body's immune system recognize and fight cancer cells. The combination of BNT113 and pembrolizumab is being investigated to see if it can provide better outcomes for patients compared to pembrolizumab alone.
Clinical Trial Overview
The clinical trial for BNT113 is a Phase II randomized trial, which means it's testing the drug's effectiveness and safety in a larger group of patients after initial safety studies have been completed. The trial has two parts:
- Safety run-in phase (Part A): This part assesses the safety and tolerability of BNT113 when combined with pembrolizumab.
- Randomized phase (Part B): This part compares BNT113 plus pembrolizumab to pembrolizumab alone to see if the combination improves overall survival and tumor response.
Eligibility Criteria
To participate in this trial, patients must meet certain criteria. Some key eligibility factors include:
- Age 18 or older
- Confirmed HPV16-positive head and neck squamous cell carcinoma
- Cancer that expresses PD-L1
- No prior systemic therapy for recurrent or metastatic disease
- Measurable disease according to specific criteria
- Adequate organ function
There are also several factors that would exclude a patient from participating, such as certain medical conditions or prior treatments.
Potential Benefits
The main goals of this study are to determine if BNT113, when combined with pembrolizumab, can:
- Improve overall survival (how long patients live)
- Increase the proportion of patients whose tumors shrink or disappear (objective response rate)
- Extend the time before the cancer progresses (progression-free survival)
- Prolong the duration of response in patients whose tumors do shrink
Safety Considerations
As with any investigational treatment, there are potential risks and side effects. The trial closely monitors for:
- Treatment-emergent adverse events (side effects that occur during treatment)
- Serious or severe side effects
- Side effects that may require dose adjustments or discontinuation of treatment
Patients considering participation in this trial should discuss potential risks and benefits thoroughly with their healthcare provider.